{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:32:14Z","timestamp":1768869134479,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-00298-7","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T08:16:39Z","timestamp":1746692199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of rosuvastatin 10\u00a0mg plus ezetimibe versus rosuvastatin 20\u00a0mg in atherosclerotic cardiovascular disease and type 2 diabetes"],"prefix":"10.1038","volume":"15","author":[{"given":"Hyo-In","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Jin","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Hyeong","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Hwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Hyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Hyung","family":"Doh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Joon","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kye Taek","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Man","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"10226","key":"298_CR1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S0140-6736(19)32008-2","volume":"395","author":"S Yusuf","year":"2020","unstructured":"Yusuf, S. et al. Modifiable risk factors, cardiovascular disease, and mortality in 155\u2008722 individuals from 21 high-income, middle-income, and low-income countries (PURE): A prospective cohort study. Lancet 395 (10226), 795\u2013808 (2020).","journal-title":"Lancet"},{"issue":"11","key":"298_CR2","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1161\/STROKEAHA.115.011164","volume":"46","author":"S Yaghi","year":"2015","unstructured":"Yaghi, S. & Elkind, M. S. Lipids and cerebrovascular disease: Research and practice. Stroke 46(11), 3322\u20133328 (2015).","journal-title":"Stroke"},{"key":"298_CR3","doi-asserted-by":"crossref","unstructured":"Grundy, S. M. et al. \/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e143. (2018).","DOI":"10.1161\/CIR.0000000000000698"},{"issue":"1","key":"298_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach, F. et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 41(1), 111\u2013188 (2020).","journal-title":"Eur. Heart J."},{"issue":"4","key":"298_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3904\/kjim.2019.188","volume":"34","author":"EJ Rhee","year":"2019","unstructured":"Rhee, E. J. et al. 2018 Guidelines for the management of dyslipidemia. Korean J. Intern. Med. 34(4), 723\u2013771 (2019).","journal-title":"Korean J. Intern. Med."},{"issue":"1","key":"298_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2013.02.027","volume":"228","author":"BW Karlson","year":"2013","unstructured":"Karlson, B. W., Nicholls, S. J., Lundman, P., Palmer, M. K. & Barter, P. J. Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <\u200970\u00a0mg\/dl or \u2265\u200950% reduction in high-risk patients: Results from VOYAGER. Atherosclerosis 228(1), 265\u2013269 (2013).","journal-title":"Atherosclerosis"},{"issue":"11","key":"298_CR7","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray, K. K. et al. EU-Wide Cross-Sectional observational study of Lipid-Modifying therapy use in secondary and primary care: The DA VINCI study. Eur. J. Prev. Cardiol. 28(11), 1279\u20131289 (2021).","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"9601","key":"298_CR8","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","volume":"370","author":"J Armitage","year":"2007","unstructured":"Armitage, J. The safety of Statins in clinical practice. Lancet 370(9601), 1781\u20131790 (2007).","journal-title":"Lancet"},{"issue":"4","key":"298_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1001\/jamacardio.2016.5922","volume":"2","author":"Y Pokharel","year":"2017","unstructured":"Pokharel, Y. et al. Adoption of the 2013 American college of cardiology\/american heart association cholesterol management guideline in cardiology practices nationwide. JAMA Cardiol. 2(4), 361\u2013369 (2017).","journal-title":"JAMA Cardiol."},{"issue":"3","key":"298_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jacc.2014.09.088","volume":"65","author":"RS Rosenson","year":"2015","unstructured":"Rosenson, R. S. et al. Underutilization of high-intensity Statin therapy after hospitalization for coronary heart disease. J. Am. Coll. Cardiol. 65(3), 270\u2013277 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"298_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ahj.2016.09.007","volume":"182","author":"F Rodriguez","year":"2016","unstructured":"Rodriguez, F. et al. Use of high-intensity Statins for patients with atherosclerotic cardiovascular disease in the veterans affairs health system: Practice impact of the new cholesterol guidelines. Am. Heart J. 182, 97\u2013102 (2016).","journal-title":"Am. Heart J."},{"issue":"3","key":"298_CR12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.amjcard.2006.08.051","volume":"99","author":"JK Liao","year":"2007","unstructured":"Liao, J. K. Safety and efficacy of Statins in Asians. Am. J. Cardiol. 99(3), 410\u2013414 (2007).","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"298_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach, F. et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS). Eur. Heart J. 41(1), 111\u2013188 (2019).","journal-title":"Eur. Heart J."},{"issue":"3","key":"298_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.amjmed.2019.07.044","volume":"133","author":"M Dauriz","year":"2020","unstructured":"Dauriz, M. et al. Fifteen-Year trends of cardiogenic shock and mortality in patients with diabetes and acute coronary syndromes. Am. J. Med. 133(3), 331\u20139e2 (2020).","journal-title":"Am. J. Med."},{"issue":"15","key":"298_CR15","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"RP Giugliano","year":"2018","unstructured":"Giugliano, R. P. et al. Benefit of adding Ezetimibe to Statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: Results from IMPROVE-IT (Improved reduction of outcomes: Vytorin efficacy international Trial). Circulation 137(15), 1571\u20131582 (2018).","journal-title":"Circulation"},{"issue":"11","key":"298_CR16","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/eurheartj\/ehac709","volume":"44","author":"YJ Lee","year":"2023","unstructured":"Lee, Y. J. et al. Moderate-intensity Statin with Ezetimibe vs. high-intensity Statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. Eur. Heart J. 44(11), 972\u2013983 (2023).","journal-title":"Eur. Heart J."},{"issue":"3","key":"298_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","volume":"42","author":"J Schubert","year":"2021","unstructured":"Schubert, J. et al. Low-density lipoprotein cholesterol reduction and Statin intensity in myocardial infarction patients and major adverse outcomes: A Swedish nationwide cohort study. Eur. Heart J. 42(3), 243\u2013252 (2021).","journal-title":"Eur. Heart J."},{"key":"298_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijcard.2017.02.099","volume":"235","author":"D Ran","year":"2017","unstructured":"Ran, D. et al. A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and Rosuvastatin versus high-dose Rosuvastatin. Int. J. Cardiol. 235, 49\u201355 (2017).","journal-title":"Int. J. Cardiol."},{"key":"298_CR19","unstructured":"2022 Korean Guidelines for the Management of Dyslipidemia. Committee of Clinical Practice Guideline of the Korean Society of Lipid and Atherosclerosis 5th edn (Korean Society of Lipid and Atherosclerosis, 2022)."},{"issue":"25","key":"298_CR20","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon, C. P. et al. Ezetimibe added to Statin therapy after acute coronary syndromes. N. Engl. J. Med. 372(25), 2387\u20132397 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"298_CR21","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.clinthera.2004.11.016","volume":"26","author":"HE Bays","year":"2004","unstructured":"Bays, H. E. et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the Ezetimibe\/simvastatin tablet compared with Ezetimibe and Simvastatin monotherapy in patients with primary hypercholesterolemia. Clin. Ther. 26(11), 1758\u20131773 (2004).","journal-title":"Clin. Ther."},{"issue":"10349","key":"298_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","volume":"400","author":"BK Kim","year":"2022","unstructured":"Kim, B. K. et al. Long-term efficacy and safety of moderate-intensity Statin with Ezetimibe combination therapy versus high-intensity Statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): A randomised, open-label, non-inferiority trial. Lancet 400(10349), 380\u2013390 (2022).","journal-title":"Lancet"},{"issue":"12","key":"298_CR23","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","volume":"78","author":"JP Howard","year":"2021","unstructured":"Howard, J. P. et al. Side effect patterns in a crossover trial of Statin, placebo, and no treatment. J. Am. Coll. Cardiol. 78(12), 1210\u20131222 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"298_CR24","doi-asserted-by":"publisher","first-page":"n135","DOI":"10.1136\/bmj.n135","volume":"372","author":"E Herrett","year":"2021","unstructured":"Herrett, E. et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. Bmj 372, n135 (2021).","journal-title":"Bmj"},{"issue":"47","key":"298_CR25","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"42","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg, H. N. et al. Triglyceride-rich lipoproteins and their remnants: Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European atherosclerosis society. Eur. Heart J. 42(47), 4791\u20134806 (2021).","journal-title":"Eur. Heart J."},{"issue":"32","key":"298_CR26","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference, B. A. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur. Heart J. 38(32), 2459\u20132472 (2017).","journal-title":"Eur. Heart J."},{"issue":"10","key":"298_CR27","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jama.2017.11467","volume":"318","author":"BA Ference","year":"2017","unstructured":"Ference, B. A. et al. Association of genetic variants related to CETP inhibitors and Statins with lipoprotein levels and cardiovascular risk. JAMA 318(10), 947\u2013956 (2017).","journal-title":"JAMA"},{"issue":"9","key":"298_CR28","doi-asserted-by":"publisher","first-page":"G1043","DOI":"10.1152\/ajpgi.00250.2011","volume":"302","author":"M Naples","year":"2012","unstructured":"Naples, M. et al. Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance. Am. J. Physiol. Gastrointest. Liver Physiol. 302(9), G1043\u2013G1052 (2012).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"1","key":"298_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.atherosclerosis.2011.03.012","volume":"217","author":"L Bozzetto","year":"2011","unstructured":"Bozzetto, L. et al. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 217(1), 142\u2013148 (2011).","journal-title":"Atherosclerosis"},{"issue":"12","key":"298_CR30","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1161\/hq1201.100260","volume":"21","author":"HR Davis Jr","year":"2001","unstructured":"Davis, H. R. Jr., Compton, D. S., Hoos, L. & Tetzloff, G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler. Thromb. Vasc Biol. 21(12), 2032\u20132038 (2001).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"9","key":"298_CR31","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.clinthera.2021.07.016","volume":"43","author":"SA Lee","year":"2021","unstructured":"Lee, S. A. et al. Effects of Fixed-dose combination of Low-intensity Rosuvastatin and Ezetimibe versus Moderate-intensity Rosuvastatin monotherapy on lipid profiles in patients with hypercholesterolemia: A randomized, Double-blind, multicenter, phase III study. Clin. Ther. 43(9), 1573\u20131589 (2021).","journal-title":"Clin. Ther."},{"issue":"5","key":"298_CR32","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1161\/01.ATV.0000216750.09611.ec","volume":"26","author":"AJ Tremblay","year":"2006","unstructured":"Tremblay, A. J., Lamarche, B., Cohn, J. S., Hogue, J. C. & Couture, P. Effect of Ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arterioscler. Thromb. Vasc Biol. 26(5), 1101\u20131106 (2006).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"9","key":"298_CR33","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jacc.2007.04.076","volume":"50","author":"KM M\u00e4ki-Pet\u00e4j\u00e4","year":"2007","unstructured":"M\u00e4ki-Pet\u00e4j\u00e4, K. M. et al. Ezetimibe and Simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J. Am. Coll. Cardiol. 50(9), 852\u2013858 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"298_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejphar.2010.02.003","volume":"633","author":"M Kalogirou","year":"2010","unstructured":"Kalogirou, M., Tsimihodimos, V. & Elisaf, M. Pleiotropic effects of ezetimibe: Do they really exist? Eur. J. Pharmacol. 633(1), 62\u201370 (2010).","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"298_CR35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40256-014-0082-3","volume":"14","author":"M Kubo","year":"2014","unstructured":"Kubo, M. et al. Add-on Ezetimibe reduces small dense low-density lipoprotein cholesterol levels without affecting absorption of eicosapentaenoic acid in patients with coronary artery disease: A pilot study. Am. J. Cardiovasc. Drugs. 14(5), 387\u2013392 (2014).","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"5","key":"298_CR36","doi-asserted-by":"publisher","first-page":"582","DOI":"10.4093\/dmj.2018.0124","volume":"43","author":"YC Hwang","year":"2019","unstructured":"Hwang, Y. C., Jun, J. E., Jeong, I. K., Ahn, K. J. & Chung, H. Y. Comparison of the efficacy of Rosuvastatin monotherapy 20\u00a0mg with Rosuvastatin 5\u00a0mg and Ezetimibe 10\u00a0mg combination therapy on lipid parameters in patients with type 2 diabetes mellitus. Diabetes Metab. J. 43 (5), 582\u2013589 (2019).","journal-title":"Diabetes Metab. J."},{"issue":"1","key":"298_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.diabres.2012.12.026","volume":"100","author":"T Tsunoda","year":"2013","unstructured":"Tsunoda, T. et al. Effects of Ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res. Clin. Pract. 100(1), 46\u201352 (2013).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"298_CR38","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s13300-020-00778-1","volume":"11","author":"J Lee","year":"2020","unstructured":"Lee, J. et al. Comparison of the efficacy and safety of Rosuvastatin\/Ezetimibe combination therapy and Rosuvastatin monotherapy on lipoprotein in patients with type 2 diabetes: Multicenter randomized controlled study. Diabetes Ther. 11(4), 859\u2013871 (2020).","journal-title":"Diabetes Ther."},{"issue":"6","key":"298_CR39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s10753-007-9041-3","volume":"30","author":"N Dagli","year":"2007","unstructured":"Dagli, N., Yavuzkir, M. & Karaca, I. The effects of high dose Pravastatin and low dose Pravastatin and Ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 30(6), 230\u2013235 (2007).","journal-title":"Inflammation"},{"issue":"2","key":"298_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.2040-1124.2011.00147.x","volume":"3","author":"S Ichimori","year":"2012","unstructured":"Ichimori, S. et al. Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes. J. Diabetes Investig. 3(2), 179\u2013184 (2012).","journal-title":"J. Diabetes Investig"},{"key":"298_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12944-015-0036-z","volume":"14","author":"I Saito","year":"2015","unstructured":"Saito, I. et al. A randomized, double-blind, placebo-controlled study of the effect of Ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia. Lipids Health Dis. 14, 40 (2015).","journal-title":"Lipids Health Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00298-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00298-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00298-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T08:16:42Z","timestamp":1746692202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00298-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-00298-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Boards (IRBs) of all participating institutions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"16012"}}